What is the CVSS score of CVE-2023-38956?

CVE-2023-38956 has a CVSS 3.1 base score of 7.5 (High). CVSS vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N. EPSS exploitation probability: 0.6%.

Bioaccess Ivs CVE-2023-38956

HIGH

Path Traversal (CWE-22)

2023-08-03 cve@mitre.org

Path Traversal Bioaccess Ivs

7.5

CVSS 3.1 · NVD

Severity by source

NVD PRIMARY

7.5 HIGH

AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Attack Vector

Network

Attack Complexity

Low

Privileges Required

None

User Interaction

None

Scope

Unchanged

Confidentiality

High

Integrity

None

Availability

None

Lifecycle Timeline

CVE Published

Aug 03, 2023 - 02:15 nvd

HIGH 7.5

DescriptionNVD

A path traversal vulnerability in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to read arbitrary files via supplying a crafted payload.

AnalysisAI

A path traversal vulnerability in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to read arbitrary files via supplying a crafted payload. Rated high severity (CVSS 7.5), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.

Technical ContextAI

This vulnerability is classified as Path Traversal (CWE-22), which allows attackers to access files and directories outside the intended path. A path traversal vulnerability in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to read arbitrary files via supplying a crafted payload. Affected products include: Zkteco Bioaccess Ivs.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Validate and canonicalize file paths. Use chroot or sandboxing. Reject input containing path separators or '../' sequences.